Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma
2014
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
Evolution of the Cancer Stem Cell Model
2014 Standout
Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice
2023 StandoutNobel
mRECIST for HCC: Performance and novel refinements
2020
Smarter drugs emerging in pancreatic cancer therapy
2014
Current Status of Liposomal Anthracycline Therapy in Metastatic Breast Cancer
2003
The photodynamic effect of far-red range phthalocyanines (AlPc and Pc green) supported by electropermeabilization in human gastric adenocarcinoma cells of sensitive and resistant type
2014
Hepatocellular carcinoma
2018 Standout
ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)
2009 Standout
Imaging the Glycosylation State of Cell Surface Glycoproteins by Two‐Photon Fluorescence Lifetime Imaging Microscopy
2013 StandoutNobel
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Biodegradable luminescent porous silicon nanoparticles for in vivo applications
2009 Standout
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma
2005
Effect of pegylation on pharmaceuticals
2003 Standout
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
2011 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update
2015
Hepatocellular carcinoma
2021 Standout
A global view of hepatocellular carcinoma: trends, risk, prevention and management
2019 Standout
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
2021 Standout
Cancer stem cells revisited
2017 Standout
Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors
2005
Colorectal cancer
2013 Standout
Integrins in prostate cancer progression
2008
Efficacy and safety of liposomal anthracyclines in Phase I/II clinical trials
2004
Current and future perspectives of liquid biopsies in genomics-driven oncology
2018 Standout
Cancer nanotechnology: opportunities and challenges
2005 Standout
Radiofrequency Ablation Followed by Conventional Radiotherapy for Medically Inoperable Stage I Non-small Cell Lung Cancer
2006
Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival
2019
Thermal ablation of tumours: biological mechanisms and advances in therapy
2014 Standout
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Recent advances with liposomes as pharmaceutical carriers
2005 Standout
Liposome-based drug delivery in breast cancer treatment
2002
Pyroptosis: mechanisms and diseases
2021 Standout
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Pegylated Liposomal Doxorubicin (Doxil®) for Metastatic Breast Cancer: The Cancer Research Network, Inc., Experience
2002
Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology
2017 Standout
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network
2009
Unraveling the therapeutic potential of the Hedgehog pathway in cancer
2013 Standout
Remodelling the extracellular matrix in development and disease
2014 Standout
Tumor delivery of macromolecular drugs based on the EPR effect
2010 Standout
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Targeted therapy in metastatic colorectal cancer – An example of personalised medicine in action
2013
Doxil® — The first FDA-approved nano-drug: Lessons learned
2012 Standout
Pegylated Liposomal Doxorubicin in the Treatment of Breast Cancer
2003
Liposomes as nanomedical devices
2015 Standout
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial
2018
Preservation of Fertility in Patients with Cancer
2009 Standout
Hepatocellular carcinoma
2022 Standout
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Photodynamic therapy – mechanisms, photosensitizers and combinations
2018 Standout
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
2005
Hepatocellular Carcinoma
2019 Standout
Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway
2017 StandoutNobel
A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
2019
Clinical Pharmacology of Liposomal Anthracyclines: Focus on Pegylated Liposomal Doxorubicin
2008
Therapeutic Nanoparticles for Drug Delivery in Cancer
2008 Standout
Recent developments in immunotherapy of cancers caused by human papillomaviruses
2020
Regulatory T cell-mediated suppression: potential role of ICER
2006 StandoutNobel
Combination therapy in combating cancer
2017 Standout
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
2020
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
2018 Standout
Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution
2014
Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity
2006 Standout
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Multiple Myeloma
2011 Standout
Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
2012 Standout
Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study
2009
Works of Lakshmi Rajdev being referenced
Vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX for first-line therapy of patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led phase II randomized study.
2013
Multimodality management of resectable gastric cancer: A review
2014
Neoadjuvant and adjuvant therapy of non-small cell lung cancer
2002
Phase II Study of Weekly Docetaxel Alone or in Combination with Trastuzumab in Patients with Metastatic Breast Cancer
2004
Pathophysiology of bone metastases
2006
Bone complications in multiple myeloma
2006
PTEN Gene Expression and Mutations in the PIK3CA Gene as Predictors of Clinical Benefit to Anti-Epidermal Growth Factor Receptor Antibody Therapy in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
2012
Clinical Protocol: A Phase I Trial of Intra Lesional RV-B7.1 Vaccine in the Treatment of Malignant Melanoma. Albert Einstein Center, Bronx, New York.
2000
Phase I Trial of Pegylated Liposomal Doxorubicin and Docetaxel in Advanced Breast Cancer
2001
Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).
2016
ADXS11-001 Lm-LLO Immunotherapy, Mitomycin, 5-fluorouracil (5-FU) and Intensity-modulated radiation therapy (IMRT) for Anal Cancer.
2017
Final analysis of a phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): A University of Chicago phase II consortium study.
2013
Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).
2016